Hernández F, Castellanos G, Valenzuela C, Catasús K, Valle R, Aguilera A. Recombinant streptokinase vs phenylephrine-based suppositories in acute hemorrhoids, randomized, controlled      trial (THERESA-3). World J Gastroenterol  2014 February 14; 20(6):1594-1601

Alfonso S, Valdés-Zayas A, Santiesteban ER, Flores YI, Areces F, Hernández M, Viada CE, Mendoza IC, Guerra PP, García E. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients. Clin Cancer Res 2014 July 15; 20(14): 3660-71

Viada C, Dupuy JF, Fors M, Lorenzo P. Stratified Cox Regression Analysis of Survival under CIMAvax®EGF Vaccine. Journal of Cancer Therapy, 2013 (4) 8-14

Robaina M, Uranga R, Fors M, Viada C. Algunas consideraciones para abordar mejor los datos incompletos en ensayos clínico. ICB digital/ Medicina Clínica Barcelona. diciembre 2012-enero (81): 2-10

Yera I, Alonso L, Valenzuela C. Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers. BMC Pharmacology and Toxicology 2013;14:44

Viada C, Ballesteros J, Fors M, Luaces P, Sánchez L. Crombet T. PCN168-A Proposed 6-Item Reduction for the European Organization for the Research and Treatment of Cancer-Quality of Core Questionnaire (EORTC QLQ-C30)-Cuban +Group of Trialists on Epidermal Growth Factor (CGT-EGF). Value in Health 2013;16 ( 7): A422

Fors M, Dupuy J, Viada C. Effectiveness of adaptive designs for phase II cancer trials. Contem. Clin. Trials. 2012 Ene; 33 (1): 223-7.

Volver a publicaciones

Páginas: 1 2 3